# Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

> **NCT07011654** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (estimated)

## Conditions studied

- Metastatic Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Naxitamab

## Key facts

- **NCT ID:** NCT07011654
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-19
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011654, "Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07011654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*